Recently the ANS List incorporated new technologies. On November 4th, the Collegiate Board of the National Supplementary Health Agency (ANS) approved the incorporation of four technologies into the List of Health Procedures and Events.
This was the 14th update in 2022, which included more therapeutic options for asthma and cancer in the list of mandatory coverage.
Understand the update proposals
The proposals to update the list, which were received through the electronic form available on the ANS website (FormRol), were at the center of the debates that took place at the 8th and 10th COSAÚDE Technical Meetings, in August and October, respectively.
ANDThey were also the subject of Public Consultation 101, two of which (Axitinib + Pembrolizumab and Cabozantinib + Nivolumab), due to having an unfavorable preliminary recommendation, still went through Public Hearing 24/2022.
All incorporation suggestions included broad social participation and careful technical analysis by the ANS, using a health technology assessment methodology, similar to countries such as England, Canada, Australia and Germany.
The List review process is dynamic and has been systematically improved. In 2022 alone, a total of 40 items were included, including procedures, medications, new indications and expansions of use, as well as important expansions for patients with global developmental disorders, such as Autism Spectrum Disorder, in addition to the end of the limits for consultations and sessions of psychology, speech therapy, occupational therapy and physiotherapy, as long as it is indicated by the doctor accompanying the patient.
Check out the technologies incorporated in Rol:
Dupilumab – Used for the treatment of severe eosinophilic asthma;
Niraparib – Used for the treatment of high-grade advanced ovarian, fallopian tube or primary peritoneal cancer, for those patients who responded completely or in part, after completion of first-line platinum-based chemotherapy in maintenance treatment;
Axitinib + Pembrolizumab – Used for the treatment of metastatic or advanced renal cell carcinoma in the first line;
Cabozantinib + Nivolumab – Also used for the treatment of metastatic or advanced renal cell carcinoma in the first line.
Use technology to benefit your healthcare provider!
The best way to ensure that your healthcare provider adapts to changes without generating problems in your operation as a whole, especially in the management of care costs, is to have implemented a good medical audit system. Being able to always be adapted to the most different requirements of the sector, it is undoubtedly the best solution for your medical bill analysis and management team to avoid errors that turn into losses.
If you are an auditor or medical account analyst and/or manager of health plan operators, Get to know SAUDI right now, a system that makes it possible to increase the capacity for technical analysis of requests, through access to support information in real time, optimizing the speed of analysis, registration and processing of authorizations.
O SAUDI system reduces the risk of delays in responding to requests, avoiding complaints from beneficiaries, through better workflow control, through the possibility of determining a response deadline for granting authorization or reasoned denial as per TISS standard.
With SAUDI all management of medical bills and healthcare costs becomes much easier, in addition to allowing your health care provider to always comply with the Legal and Governmental requirements of the health plan sector and that the performance of the your work be recognized for the efficiency, agility and transparency of processes.
If you liked this content, subscribe to our newsletter and follow our social networks to have access to more useful information. We are present in Facebook, Linkedin It is Instagram.
Check out these success stories!
Reduction of 94% in medical disallowances at Unimed Extremo Sul – Check out this success story!
